Prevalence of group C streptococcus and Fusobacterium necrophorum in patients with sore throat: A meta-analysis

Christian Marchello, Mark H. Ebell

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

PURPOSE The prevalence of Group C beta-hemolytic streptococcus and Fusobacterium necrophorum among patients with sore throat in the outpatient setting has not been previously summarized. We set out to derive prevalence information from the existing literature. METHODS We performed a systematic review of MEDLINE for studies reporting the prevalence of F necrophorum or Group C streptococcus or both in prospective, consecutive series of outpatients with sore throat, as well as laboratory-based studies of throat cultures submitted from primary care. We limited searches to studies where the majority of data was collected after January 1, 2000, to reflect contemporary microbiological methods and prevalences. Each author independently reviewed the articles for inclusion and abstraction of data; we resolved discrepancies by consensus discussion. We then performed a meta-analysis to calculate the pooled prevalence estimates using a random effects model of raw proportions. RESULTS A total of 16 studies met our inclusion criteria. The overall prevalences of Group C streptococcus and F necrophorum were 6.1% (95% CI, 3.2%-9.0%) and 18.9% (95% CI, 10.5%-27.2%), respectively. When stratified by study type, the prevalences of Group C streptococcus and F necrophorum in laboratory-based studies were 6.6% (95% CI, -1.0% to 14.2%) and 18.8% (95% CI, 6.5%-31.1%), respectively. In primary care patients with sore throat, Group C streptococcus had a prevalence of 6.1% (95% CI, 3.1%-9.2%), while F necrophorum had a prevalence of 19.4% (95% CI, 14.7%-24.1%). CONCLUSIONS Group C streptococcus and Fusobacterium necrophorum are commonly detected in patients with acute pharyngitis. Research is needed, however, to determine whether these bacteria are truly pathogenic in patients with pharyngitis and whether antibiotics reduce the duration of symptoms or the likelihood of complications.

Original languageEnglish (US)
Pages (from-to)567-574
Number of pages8
JournalAnnals of family medicine
Volume14
Issue number6
DOIs
StatePublished - Nov 1 2016

Fingerprint

Fusobacterium necrophorum
Pharyngitis
Streptococcus
Meta-Analysis
Primary Health Care
Outpatients
Cross-Sectional Studies
Pharynx
MEDLINE
Anti-Bacterial Agents
Bacteria

Keywords

  • Fusobacterium necrophorum prevalence
  • Group C streptococcus prevalence
  • Pharyngitis
  • Primary care

ASJC Scopus subject areas

  • Family Practice

Cite this

Prevalence of group C streptococcus and Fusobacterium necrophorum in patients with sore throat : A meta-analysis. / Marchello, Christian; Ebell, Mark H.

In: Annals of family medicine, Vol. 14, No. 6, 01.11.2016, p. 567-574.

Research output: Contribution to journalReview article

@article{df5ae7eb1e4a4aa08ca2076b63dc1fd0,
title = "Prevalence of group C streptococcus and Fusobacterium necrophorum in patients with sore throat: A meta-analysis",
abstract = "PURPOSE The prevalence of Group C beta-hemolytic streptococcus and Fusobacterium necrophorum among patients with sore throat in the outpatient setting has not been previously summarized. We set out to derive prevalence information from the existing literature. METHODS We performed a systematic review of MEDLINE for studies reporting the prevalence of F necrophorum or Group C streptococcus or both in prospective, consecutive series of outpatients with sore throat, as well as laboratory-based studies of throat cultures submitted from primary care. We limited searches to studies where the majority of data was collected after January 1, 2000, to reflect contemporary microbiological methods and prevalences. Each author independently reviewed the articles for inclusion and abstraction of data; we resolved discrepancies by consensus discussion. We then performed a meta-analysis to calculate the pooled prevalence estimates using a random effects model of raw proportions. RESULTS A total of 16 studies met our inclusion criteria. The overall prevalences of Group C streptococcus and F necrophorum were 6.1{\%} (95{\%} CI, 3.2{\%}-9.0{\%}) and 18.9{\%} (95{\%} CI, 10.5{\%}-27.2{\%}), respectively. When stratified by study type, the prevalences of Group C streptococcus and F necrophorum in laboratory-based studies were 6.6{\%} (95{\%} CI, -1.0{\%} to 14.2{\%}) and 18.8{\%} (95{\%} CI, 6.5{\%}-31.1{\%}), respectively. In primary care patients with sore throat, Group C streptococcus had a prevalence of 6.1{\%} (95{\%} CI, 3.1{\%}-9.2{\%}), while F necrophorum had a prevalence of 19.4{\%} (95{\%} CI, 14.7{\%}-24.1{\%}). CONCLUSIONS Group C streptococcus and Fusobacterium necrophorum are commonly detected in patients with acute pharyngitis. Research is needed, however, to determine whether these bacteria are truly pathogenic in patients with pharyngitis and whether antibiotics reduce the duration of symptoms or the likelihood of complications.",
keywords = "Fusobacterium necrophorum prevalence, Group C streptococcus prevalence, Pharyngitis, Primary care",
author = "Christian Marchello and Ebell, {Mark H.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1370/afm.2005",
language = "English (US)",
volume = "14",
pages = "567--574",
journal = "Annals of Family Medicine",
issn = "1544-1709",
publisher = "Annals of Family Medicine, Inc",
number = "6",

}

TY - JOUR

T1 - Prevalence of group C streptococcus and Fusobacterium necrophorum in patients with sore throat

T2 - A meta-analysis

AU - Marchello, Christian

AU - Ebell, Mark H.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - PURPOSE The prevalence of Group C beta-hemolytic streptococcus and Fusobacterium necrophorum among patients with sore throat in the outpatient setting has not been previously summarized. We set out to derive prevalence information from the existing literature. METHODS We performed a systematic review of MEDLINE for studies reporting the prevalence of F necrophorum or Group C streptococcus or both in prospective, consecutive series of outpatients with sore throat, as well as laboratory-based studies of throat cultures submitted from primary care. We limited searches to studies where the majority of data was collected after January 1, 2000, to reflect contemporary microbiological methods and prevalences. Each author independently reviewed the articles for inclusion and abstraction of data; we resolved discrepancies by consensus discussion. We then performed a meta-analysis to calculate the pooled prevalence estimates using a random effects model of raw proportions. RESULTS A total of 16 studies met our inclusion criteria. The overall prevalences of Group C streptococcus and F necrophorum were 6.1% (95% CI, 3.2%-9.0%) and 18.9% (95% CI, 10.5%-27.2%), respectively. When stratified by study type, the prevalences of Group C streptococcus and F necrophorum in laboratory-based studies were 6.6% (95% CI, -1.0% to 14.2%) and 18.8% (95% CI, 6.5%-31.1%), respectively. In primary care patients with sore throat, Group C streptococcus had a prevalence of 6.1% (95% CI, 3.1%-9.2%), while F necrophorum had a prevalence of 19.4% (95% CI, 14.7%-24.1%). CONCLUSIONS Group C streptococcus and Fusobacterium necrophorum are commonly detected in patients with acute pharyngitis. Research is needed, however, to determine whether these bacteria are truly pathogenic in patients with pharyngitis and whether antibiotics reduce the duration of symptoms or the likelihood of complications.

AB - PURPOSE The prevalence of Group C beta-hemolytic streptococcus and Fusobacterium necrophorum among patients with sore throat in the outpatient setting has not been previously summarized. We set out to derive prevalence information from the existing literature. METHODS We performed a systematic review of MEDLINE for studies reporting the prevalence of F necrophorum or Group C streptococcus or both in prospective, consecutive series of outpatients with sore throat, as well as laboratory-based studies of throat cultures submitted from primary care. We limited searches to studies where the majority of data was collected after January 1, 2000, to reflect contemporary microbiological methods and prevalences. Each author independently reviewed the articles for inclusion and abstraction of data; we resolved discrepancies by consensus discussion. We then performed a meta-analysis to calculate the pooled prevalence estimates using a random effects model of raw proportions. RESULTS A total of 16 studies met our inclusion criteria. The overall prevalences of Group C streptococcus and F necrophorum were 6.1% (95% CI, 3.2%-9.0%) and 18.9% (95% CI, 10.5%-27.2%), respectively. When stratified by study type, the prevalences of Group C streptococcus and F necrophorum in laboratory-based studies were 6.6% (95% CI, -1.0% to 14.2%) and 18.8% (95% CI, 6.5%-31.1%), respectively. In primary care patients with sore throat, Group C streptococcus had a prevalence of 6.1% (95% CI, 3.1%-9.2%), while F necrophorum had a prevalence of 19.4% (95% CI, 14.7%-24.1%). CONCLUSIONS Group C streptococcus and Fusobacterium necrophorum are commonly detected in patients with acute pharyngitis. Research is needed, however, to determine whether these bacteria are truly pathogenic in patients with pharyngitis and whether antibiotics reduce the duration of symptoms or the likelihood of complications.

KW - Fusobacterium necrophorum prevalence

KW - Group C streptococcus prevalence

KW - Pharyngitis

KW - Primary care

UR - http://www.scopus.com/inward/record.url?scp=84995704353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995704353&partnerID=8YFLogxK

U2 - 10.1370/afm.2005

DO - 10.1370/afm.2005

M3 - Review article

C2 - 28376443

AN - SCOPUS:84995704353

VL - 14

SP - 567

EP - 574

JO - Annals of Family Medicine

JF - Annals of Family Medicine

SN - 1544-1709

IS - 6

ER -